134 related articles for article (PubMed ID: 27328277)
1. Trabectedin for the treatment of soft tissue sarcomas.
De Sanctis R; Marrari A; Santoro A
Expert Opin Pharmacother; 2016 Aug; 17(11):1569-77. PubMed ID: 27328277
[TBL] [Abstract][Full Text] [Related]
2. Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report.
Bongiovanni A; Riva N; Ricci M; Mercatali L; Liverani C; La Manna F; De Vita A; Cavaliere D; Pieri F; Oboldi D; Verdecchia GM; Amadori D; Ibrahim T
BMC Cancer; 2015 Dec; 15():998. PubMed ID: 26695071
[TBL] [Abstract][Full Text] [Related]
3. Trabectedin and radiotherapy in soft tissue sarcomas: friends or foes?
Assi T; Cesne AL
Future Oncol; 2023 Sep; 19(28):1893-1896. PubMed ID: 37781755
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review.
Sharma S; Takyar S; Manson SC; Powell S; Penel N
BMC Cancer; 2013 Aug; 13():385. PubMed ID: 23937858
[TBL] [Abstract][Full Text] [Related]
5. HMGA1 regulates trabectedin sensitivity in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study.
Moura DS; Mondaza-Hernandez JL; Sanchez-Bustos P; Peña-Chilet M; Cordero-Varela JA; Lopez-Alvarez M; Carrillo-Garcia J; Martin-Ruiz M; Romero-Gonzalez P; Renshaw-Calderon M; Ramos R; Marcilla D; Alvarez-Alegret R; Agra-Pujol C; Izquierdo F; Ortega-Medina L; Martin-Davila F; Hernandez-Leon CN; Romagosa C; Salgado MAV; Lavernia J; Bagué S; Mayodormo-Aranda E; Alvarez R; Valverde C; Martinez-Trufero J; Castilla-Ramirez C; Gutierrez A; Dopazo J; Hindi N; Garcia-Foncillas J; Martin-Broto J
Cell Mol Life Sci; 2024 May; 81(1):219. PubMed ID: 38758230
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma.
Thornton KA
Core Evid; 2010 Jun; 4():191-8. PubMed ID: 20694075
[TBL] [Abstract][Full Text] [Related]
7. Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial.
Italiano A; Touati N; Litière S; Collin F; Pourquier P; Gronchi A
Cancer Med; 2018 May; 7(5):1575-1577. PubMed ID: 29656586
[TBL] [Abstract][Full Text] [Related]
8. A Clear Cell Sarcoma Case: A Diagnostic and Treatment Challenge, with a Promising Response to Trabectedin.
Galera M; Álvarez R; Arregui M; Paniagua M; Álvarez A; González Crisostomo RA; Díazgranados A; Gutiérrez N; Calles A; Agra C
Case Rep Oncol; 2023; 16(1):1542-1550. PubMed ID: 38074516
[TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations.
In GK; Hu JS; Tseng WW
Ther Adv Med Oncol; 2017 Aug; 9(8):533-550. PubMed ID: 28794805
[TBL] [Abstract][Full Text] [Related]
10. Synthetic studies on Et-743. Assembly of the pentacyclic core and a formal total synthesis.
Fishlock D; Williams RM
J Org Chem; 2008 Dec; 73(24):9594-600. PubMed ID: 18687003
[TBL] [Abstract][Full Text] [Related]
11. Trabectedin and its potential in the treatment of soft tissue sarcoma.
Cassier PA; Dufresne A; Blay JY; Fayette J
Ther Clin Risk Manag; 2008 Feb; 4(1):109-16. PubMed ID: 18728699
[TBL] [Abstract][Full Text] [Related]
12. New drugs and combinations for the treatment of soft-tissue sarcoma: a review.
Somaiah N; von Mehren M
Cancer Manag Res; 2012; 4():397-411. PubMed ID: 23226072
[TBL] [Abstract][Full Text] [Related]
13. Metabolic Clues to Bile Acid Patterns and Prolonged Survival in Patients with Metastatic Soft-Tissue Sarcoma Treated with Trabectedin.
Miolo G; Buonadonna A; Scalone S; Lombardi D; Della Puppa L; Steffan A; Corona G
Metabolites; 2023 Sep; 13(10):. PubMed ID: 37887360
[TBL] [Abstract][Full Text] [Related]
14. Systemic Therapy for Advanced Soft Tissue Sarcoma.
Sheng JY; Movva S
Surg Clin North Am; 2016 Oct; 96(5):1141-56. PubMed ID: 27542647
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of trabectedin for the treatment of liposarcoma.
Zijoo R; von Mehren M
Expert Opin Pharmacother; 2016 Oct; 17(14):1953-62. PubMed ID: 27615729
[TBL] [Abstract][Full Text] [Related]
16. Liposarcoma: Multimodality Management and Future Targeted Therapies.
Crago AM; Dickson MA
Surg Oncol Clin N Am; 2016 Oct; 25(4):761-73. PubMed ID: 27591497
[TBL] [Abstract][Full Text] [Related]
17. Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin.
Desar IM; Constantinidou A; Kaal SE; Jones RL; van der Graaf WT
Cancer Manag Res; 2016; 8():95-104. PubMed ID: 27574465
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue Sarcoma.
Colosia A; Khan S; Hackshaw MD; Oglesby A; Kaye JA; Skolnik JM
Sarcoma; 2016; 2016():3597609. PubMed ID: 27516726
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
